Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes

Seminars in Cell and Developmental Biology

Volumn 54, Issue , 2016, Pages 2-10

  Kazemi Bajestani, Seyyed Mohammad Reza ^a   Mazurak, Vera C ^a   Baracos, Vickie ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cancer; Computed tomography; Fat; Muscle

Indexed keywords

DOXORUBICIN;

BODY COMPOSITION; BODY FAT; CACHEXIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; DISEASE COURSE; HUMAN; LENGTH OF STAY; LUMBAR VERTEBRA; MUSCLE ATROPHY; MUSCLE MASS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE INFECTION; QUANTITATIVE ANALYSIS; RADIATION ATTENUATION; REVIEW; SARCOPENIA; SKELETAL MUSCLE; SUBCUTANEOUS DRUG ADMINISTRATION; SURGICAL INFECTION; SYSTEMATIC REVIEW; VISCERA; ADIPOSE TISSUE; AGED; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; FEMALE; MALE; MIDDLE AGED; NEOPLASM; PATHOLOGY; POSTOPERATIVE COMPLICATION; PROCEDURES; PROGNOSIS; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ADIPOSE TISSUE; AGED; AGED, 80 AND OVER; CACHEXIA; DISEASE PROGRESSION; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84941243626     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.09.001     Document Type: Review

References (78)

1. Fearon K., Arends J., Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat. Rev. Clin. Oncol. 2013, 10:90-99.
2. Baracos V., Kazemi-Bajestani S.M. Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses. Int. J. Biochem. Cell Biol. 2013, 45:2302-2308.
3. Hubbard J.M., Cohen H.J., Muss H.B. Incorporating biomarkers into cancer and aging research. J. Clin. Oncol. 2014.
4. Baracos V., Caserotti P., Earthman C.P., Fields D., Gallagher D., Hall K.D., et al. Advances in the science and application of body composition measurement. J. Parenter. Enteral Nutr. 2012, 36:96-107.
5. Heymsfield S.B., Gallagher D., Visser M., Nunez C., Wang Z.M. Measurement of skeletal muscle: laboratory and epidemiological methods. J. Gerontol. A: Biol. Sci. Med. Sci. 1995, 50. Spec No.: 23-9.
6. MacDonald A.J., Greig C.A., Baracos V. The advantages and limitations of cross-sectional body composition analysis. Curr. Opin. Support Palliat. Care 2011, 5:342-349.
7. Shen W., Punyanitya M., Wang Z., Gallagher D., St-Onge M.P., Albu J., et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J. Appl. Physiol. 1985, 2004(97):2333-2338.
8. Lee S., Janssen I., Ross R. Interindividual variation in abdominal subcutaneous and visceral adipose tissue: influence of measurement site. J. Appl. Physiol. 1985, 97(2004):948-954.
9. Prado C.M., Sawyer M.B., Ghosh S., Lieffers J.R., Esfandiari N., Antoun S., et al. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?. Am. J. Clin. Nutr. 2013, 98:1012-1019.
10. Evans W.J. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am. J. Clin. Nutr. 2010, 91:1123S-1127S.
11. Balentine C.J., Enriquez J., Fisher W., Hodges S., Bansal V., Sansgiry S., et al. Intra-abdominal fat predicts survival in pancreatic cancer. J. Gastrointest. Surg. 2010, 14:1832-1837.
12. Mathur A., Hernandez J., Shaheen F., Shroff M., Dahal S., Morton C., et al. Preoperative computed tomography measurements of pancreatic steatosis and visceral fat: prognostic markers for dissemination and lethality of pancreatic adenocarcinoma. HPB 2011, 13:404-410.
13. Joglekar S., Asghar A., Mott S.L., Johnson B.E., Button A.M., Clark E., et al. Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. J. Surg. Oncol. 2014.
14. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
15. Fogelman D.R., Holmes H., Mohammed K., Katz M.H., Prado C.M., Lieffers J., et al. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?. J. Cachexia Sarcopenia Muscle 2014.
16. Murphy R.A., Wilke M.S., Perrine M., Pawlowicz M., Mourtzakis M., Lieffers J.R., et al. Loss of adipose tissue and plasma phospholipids: relationship to survival in advanced cancer patients. Clin. Nutr. 2010, 29:482-487.
17. Parsons H.A., Baracos V.E., Dhillon N., Hong D.S., Kurzrock R. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS ONE 2012, 7:e29330.
18. Parsons H.A., Tsimberidou A.M., Pontikos M., Fu S., Hong D., Wen S., et al. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr. Cancer 2012, 64:206-217.
19. Tan B.H., Birdsell L.A., Martin L., Baracos V.E., Fearon K.C. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin. Cancer Res. 2009, 15:6973-6979.
20. Murphy R.A., Mourtzakis M., Chu Q.S., Baracos V.E., Reiman T., Mazurak V.C. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 2011, 117:1775-1782.
21. Prado C.M., Lieffers J.R., McCargar L.J., Reiman T., Sawyer M.B., Martin L., et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008, 9:629-635.
22. Esfandiari N., Ghosh S., Prado C.M., Martin L., Mazurak V., Baracos V. Age, obesity, sarcopenia, and proximity to death explain reduced mean muscle attenuation in patients with advanced cancer. J. Frailty Aging 2014, 3(1):3-8.
23. Psutka S.P., Boorjian S.A., Moynagh M.R., Schmit G.D., Frank I., Carrasco A., et al. Mortality after radical cystectomy: the impact of obesity versus adiposity after adjusting for skeletal muscle wasting. J. Urol. 2014.
24. Martin L., Birdsell L., Macdonald N., Reiman T., Clandinin M.T., McCargar L.J., et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 2013, 31:1539-1547.
25. Baumgartner R.N., Koehler K.M., Gallagher D., Romero L., Heymsfield S.B., Ross R.R., et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am. J. Epidemiol. 1998, 147:755-763.
26. Awad S., Tan B.H., Cui H., Bhalla A., Fearon K.C., Parsons S.L., et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin. Nutr. 2012, 31:74-77.
27. Dalal S., Hui D., Bidaut L., Lem K., Del Fabbro E., Crane C., et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J. Pain Symptom Manag. 2012, 44:181-191.
28. Voron T., Tselikas L., Pietrasz D., Pigneur F., Laurent A., Compagnon P., et al. Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma. Ann. Surg. 2014.
29. Yip C., Goh V., Davies A., Gossage J., Mitchell-Hay R., Hynes O., et al. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur. Radiol. 2014.
30. Antoun S., Baracos V.E., Birdsell L., Escudier B., Sawyer M.B. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann. Oncol. 2010, 21:1594-1598.
31. Huillard O., Mir O., Peyromaure M., Tlemsani C., Giroux J., Boudou-Rouquette P., et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br. J. Cancer 2013, 108:1034-1041.
32. Mir O., Coriat R., Blanchet B., Durand J.P., Boudou-Rouquette P., Michels J., et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS ONE 2012, 7:e37563.
33. Mir O., Coriat R., Boudou-Rouquette P., Ropert S., Durand J.P., Cessot A., et al. Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. Med. Oncol. 2012, 29:2793-2799.
34. Cooper A.B., Slack R., Fogelman D., Holmes H.M., Petzel M., Parker N., et al. Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer. Ann. Surg. Oncol. 2014.
35. Camus V., Lanic H., Kraut J., Modzelewski R., Clatot F., Picquenot J.M., et al. Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Eur. J. Haematol. 2014, 93:9-18.
36. Lanic H., Kraut-Tauzia J., Modzelewski R., Clatot F., Mareschal S., Picquenot J.M., et al. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk. Lymphoma 2013.
37. Miyamoto Y., Baba Y., Sakamoto Y., Ohuchi M., Tokunaga R., Kurashige J., et al. Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer. Ann. Surg. Oncol. 2015.
38. Harimoto N., Shirabe K., Yamashita Y.I., Ikegami T., Yoshizumi T., Soejima Y., et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br. J. Surg. 2013, 100:1523-1530.
39. Iritani S., Imai K., Takai K., Hanai T., Ideta T., Miyazaki T., et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J. Gastroenterol. 2014.
40. Prado C.M., Baracos V.E., McCargar L.J., Reiman T., Mourtzakis M., Tonkin K., et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin. Cancer Res. 2009, 15:2920-2926.
41. Tan B.H., Brammer K., Randhawa N., Welch N.T., Parsons S.L., James E.J., et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur. J. Surg. Oncol. 2014.
42. Barret M., Antoun S., Dalban C., Malka D., Mansourbakht T., Zaanan A., et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr. Cancer 2014, 66:583-589.
43. Cousin S., Hollebecque A., Koscielny S., Mir O., Varga A., Baracos V.E., et al. Low skeletal muscle is associated with toxicity in patients included in phase I trials. Investig. New Drugs 2013.
44. Massicotte M.H., Borget I., Broutin S., Baracos V.E., Leboulleux S., Baudin E., et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J. Clin. Endocrinol. Metab. 2013, 98:2401-2408.
45. Cushen S.J., Power D.G., Teo M.Y., Maceneaney P., Maher M.M., McDermott R., et al. Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib. Am. J. Clin. Oncol. 2014.
46. Wong A.L., Seng K.Y., Ong E.M., Wang L.Z., Oscar H., Cordero M.T., et al. Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res. Treat. 2014, 144:143-152.
47. Lieffers J.R., Bathe O.F., Fassbender K., Winget M., Baracos V.E. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br. J. Cancer 2012, 107:931-936.
48. Sharma P., Zargar-Shoshtari K., Caracciolo J.T., Richard G.J., Poch M.A., Pow-Sang J., et al. Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World J. Urol. 2015.
49. Reisinger K.W., van Vugt J.L., Tegels J.J., Snijders C., Hulsewe K.W., Hoofwijk A.G., et al. Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. Ann. Surg. 2015, 261:345-352.
50. Lodewick T.M., van Nijnatten T.J., van Dam R.M., van Mierlo K., Dello S.A., Neumann U.P., et al. Are sarcopenia, obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases?. HPB 2014.
51. Torres M.L., Hartmann L.C., Cliby W.A., Kalli K.R., Young P.M., Weaver A.L., et al. Nutritional status, CT body composition measures and survival in ovarian cancer. Gynecol. Oncol. 2013, 129:548-553.
52. Prado C.M., Bekaii-Saab T., Doyle L.A., Shrestha S., Ghosh S., Baracos V.E., et al. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br. J. Cancer 2012, 106:1583-1586.
53. Veasey Rodrigues H., Baracos V.E., Wheler J.J., Parsons H.A., Hong D.S., Naing A., et al. Body composition and survival in the early clinical trials setting. Eur. J. Cancer 2013, 49:3068-3075.
54. van Vledder M.G., Levolger S., Ayez N., Verhoef C., Tran T.C., Ijzermans J.N. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br. J. Surg. 2012, 99:550-557.
55. Meza-Junco J., Montano-Loza A.J., Baracos V.E., Prado C.M., Bain V.G., Beaumont C., et al. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J. Clin. Gastroenterol. 2013, 47:861-870.
56. Psutka S.P., Carrasco A., Schmit G.D., Moynagh M.R., Boorjian S.A., Frank I., et al. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer 2014, 120:2910-2918.
57. Stene G.B., Helbostad J.L., Amundsen T., Sorhaug S., Hjelde H., Kaasa S., et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol. 2014, 1-9.
58. Antoun S., Lanoy E., Iacovelli R., Albiges-Sauvin L., Loriot Y., Merad-Taoufik M., et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer 2013, 119:3377-3384.
59. Di Sebastiano K.M., Yang L., Zbuk K., Wong R.K., Chow T., Koff D., et al. Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia. Br. J. Nutr. 2013, 109:302-312.
60. Lieffers J.R., Mourtzakis M., Hall K.D., McCargar L.J., Prado C.M., Baracos V.E. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am. J. Clin. Nutr. 2009, 89:1173-1179.
61. Antoun S., Birdsell L., Sawyer M.B., Venner P., Escudier B., Baracos V.E. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J. Clin. Oncol. 2010, 28:1054-1060.
62. Pezaro C., Mukherji D., Tunariu N., Cassidy A.M., Omlin A., Bianchini D., et al. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. Br. J. Cancer 2013, 109:325-331.
63. Mourtzakis M., Prado C.M., Lieffers J.R., Reiman T., McCargar L.J., Baracos V.E. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 2008, 33:997-1006.
64. Richards C.H., Roxburgh C.S., MacMillan M.T., Isswiasi S., Robertson E.G., Guthrie G.K., et al. The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS ONE 2012, 7:e41883.
65. Aubrey J., Esfandiari N., Baracos V., Buteau F., Frenette J., Putman C., et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol. (Oxf.) 2014.
66. Gallagher D., Visser M., De Meersman R.E., Sepulveda D., Baumgartner R.N., Pierson R.N., et al. Appendicular skeletal muscle mass: effects of age, gender, and ethnicity. J. Appl. Physiol. 1997, 1985(83):229-239.
67. Obisesan T.O., Aliyu M.H., Bond V., Adams R.G., Akomolafe A., Rotimi C.N. Ethnic and age-related fat free mass loss in older Americans: the Third National Health and Nutrition Examination Survey (NHANES III). BMC Public Health 2005, 5:41.
68. Wang Z., Heo M., Lee R.C., Kotler D.P., Withers R.T., Heymsfield S.B. Muscularity in adult humans: proportion of adipose tissue-free body mass as skeletal muscle. Am. J. Hum. Biol. 2001, 13:612-619.
69. Antoun S., Borget I., Lanoy E. Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr. Opin. Support Palliat. Care 2013, 7:383-389.
70. Del Fabbro E., Parsons H., Warneke C.L., Pulivarthi K., Litton J.K., Dev R., et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist 2012, 17:1240-1245.
71. Kalantar-Zadeh K., Horwich T.B., Oreopoulos A., Kovesdy C.P., Younessi H., Anker S.D., et al. Risk factor paradox in wasting diseases. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10:433-442.
72. Prado C.M., Antoun S., Sawyer M.B., Baracos V.E. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr. Opin. Clin. Nutr. Metab. Care 2011, 14:250-254.
73. Prado C.M., Lima I.S., Baracos V.E., Bies R.R., McCargar L.J., Reiman T., et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother. Pharmacol. 2011, 67:93-101.
74. Lecker S.H., Jagoe R.T., Gilbert A., Gomes M., Baracos V., Bailey J., et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 2004, 18:39-51.
75. Boettcher M., Machann J., Stefan N., Thamer C., Haring H.U., Claussen C.D., et al. Intermuscular adipose tissue (IMAT): association with other adipose tissue compartments and insulin sensitivity. J. Magn. Reson. Imaging 2009, 29:1340-1345.
76. Tuttle L.J., Sinacore D.R., Cade W.T., Mueller M.J. Lower physical activity is associated with higher intermuscular adipose tissue in people with type 2 diabetes and peripheral neuropathy. Phys. Ther. 2011, 91:923-930.
77. Prado C.M., Baracos V.E., McCargar L.J., Mourtzakis M., Mulder K.E., Reiman T., et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin. Cancer Res. 2007, 13:3264-3268.
78. Poterucha T., Burnette B., Jatoi A. A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Med. Oncol. 2012, 29:1005-1009.